Patients’ characteristics
| Charachteristic . | n (%) . |
|---|---|
| Female:male ratio | 55.1:44.9 |
| Median age | 64 (IQR = 17) |
| Period of diagnosis | |
| <1990 | 1 (0.3) |
| 1990-1994 | 11 (3.6) |
| 1995-1999 | 32 (10.6) |
| 2000-2004 | 75 (24.8) |
| 2005-2009 | 142 (46.9) |
| 2010-2014 | 32 (10.6) |
| >2015 | 10 (3.3) |
| ECOG scale | |
| 0-1 | 191 (63.0) |
| >1 | 16 (5.3) |
| Missing | 96 (31.7) |
| Ann Arbor stage | |
| I | 0 |
| II | 0 |
| III | 0 |
| IV | 272 (89.8) |
| missing | 31 (10.2) |
| B symptoms | |
| Yes | 54 (17.8) |
| No | 181 (59.7) |
| Missing | 68 (22.5) |
| Extrahilar lymph node | |
| Yes | 61 (20.1) |
| No | 156 (51.5) |
| Missing | 86 (28.4) |
| Median hemoglobin | 11.6 g/dL (IQR=2.9) |
| HPLL (<9.5 g/dL) | 41 (13.5) |
| ILL (<12 g/dL) | 142 (46.9) |
| Low (<10 g/dL) | 56 (18.5) |
| Missing | 54 (17.8) |
| Median platelets | 125 ×109/L (IQR=70) |
| Low (<80 ×109/L) | 33 (10.9) |
| Missing | 62 (20.5) |
| Median lymphocytes | 3.3 ×109/L (IQR=7.65) |
| High (>5.0 × 109/L) | 84 (27.7) |
| Normal | 135 (44.6) |
| Missing | 84 (27.7) |
| Median LDH | 387.5 U/L (IQR=249) |
| High (>ULN) | 87 (28.7) |
| Normal | 113 (37.3) |
| Missing | 103 (34.0) |
| Median albumin | 40 g/L (IQR=6.0) |
| Low (<35 g/L) | 23 (7.6) |
| Normal | 131 (43.2) |
| Missing | 149 (49.2) |
| Median β2-microglobulin | 3.6 mg/L (IQR=2.07) |
| High (>2.5 mg/L) | 96 (31.7) |
| Normal | 34 (11.2) |
| Missing | 173 (57.1) |
| HCV | |
| Positive | 12 (4.0) |
| Negative | 175 (57.7) |
| Missing | 116 (38.3) |
| Serum monoclonal component | |
| Yes | 61 (20.1) |
| IgG | 21(34.5) |
| IgM | 39 (63.9) |
| Missing | 1 (1.6) |
| No | 138 (45.6) |
| Missing | 104 (34.3) |
| Charachteristic . | n (%) . |
|---|---|
| Female:male ratio | 55.1:44.9 |
| Median age | 64 (IQR = 17) |
| Period of diagnosis | |
| <1990 | 1 (0.3) |
| 1990-1994 | 11 (3.6) |
| 1995-1999 | 32 (10.6) |
| 2000-2004 | 75 (24.8) |
| 2005-2009 | 142 (46.9) |
| 2010-2014 | 32 (10.6) |
| >2015 | 10 (3.3) |
| ECOG scale | |
| 0-1 | 191 (63.0) |
| >1 | 16 (5.3) |
| Missing | 96 (31.7) |
| Ann Arbor stage | |
| I | 0 |
| II | 0 |
| III | 0 |
| IV | 272 (89.8) |
| missing | 31 (10.2) |
| B symptoms | |
| Yes | 54 (17.8) |
| No | 181 (59.7) |
| Missing | 68 (22.5) |
| Extrahilar lymph node | |
| Yes | 61 (20.1) |
| No | 156 (51.5) |
| Missing | 86 (28.4) |
| Median hemoglobin | 11.6 g/dL (IQR=2.9) |
| HPLL (<9.5 g/dL) | 41 (13.5) |
| ILL (<12 g/dL) | 142 (46.9) |
| Low (<10 g/dL) | 56 (18.5) |
| Missing | 54 (17.8) |
| Median platelets | 125 ×109/L (IQR=70) |
| Low (<80 ×109/L) | 33 (10.9) |
| Missing | 62 (20.5) |
| Median lymphocytes | 3.3 ×109/L (IQR=7.65) |
| High (>5.0 × 109/L) | 84 (27.7) |
| Normal | 135 (44.6) |
| Missing | 84 (27.7) |
| Median LDH | 387.5 U/L (IQR=249) |
| High (>ULN) | 87 (28.7) |
| Normal | 113 (37.3) |
| Missing | 103 (34.0) |
| Median albumin | 40 g/L (IQR=6.0) |
| Low (<35 g/L) | 23 (7.6) |
| Normal | 131 (43.2) |
| Missing | 149 (49.2) |
| Median β2-microglobulin | 3.6 mg/L (IQR=2.07) |
| High (>2.5 mg/L) | 96 (31.7) |
| Normal | 34 (11.2) |
| Missing | 173 (57.1) |
| HCV | |
| Positive | 12 (4.0) |
| Negative | 175 (57.7) |
| Missing | 116 (38.3) |
| Serum monoclonal component | |
| Yes | 61 (20.1) |
| IgG | 21(34.5) |
| IgM | 39 (63.9) |
| Missing | 1 (1.6) |
| No | 138 (45.6) |
| Missing | 104 (34.3) |
Extrahilar lymph nodes were regional in all cases and affected the celiac region.
HPLL, Hb threshold by the Splenic Marginal Zone Lymphoma Study Group (HPLL) score; IIL, Hb threshold by the Interguppo Italiano Linfomi (IIL) score.